<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Opin Nephrol Hypertens</journal-id><journal-id journal-id-type="iso-abbrev">Curr Opin Nephrol Hypertens</journal-id><journal-id journal-id-type="pmc-domain-id">2035</journal-id><journal-id journal-id-type="pmc-domain">lwwopen</journal-id><journal-id journal-id-type="publisher-id">CONHY</journal-id><journal-title-group><journal-title>Current Opinion in Nephrology and Hypertension</journal-title></journal-title-group><issn pub-type="ppub">1062-4821</issn><issn pub-type="epub">1473-6543</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Lippincott Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12144538</article-id><article-id pub-id-type="pmcid-ver">PMC12144538.1</article-id><article-id pub-id-type="pmcaid">12144538</article-id><article-id pub-id-type="pmcaiid">12144538</article-id><article-id pub-id-type="pmid">40237064</article-id><article-id pub-id-type="doi">10.1097/MNH.0000000000001078</article-id><article-id pub-id-type="publisher-id">MNH340406</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>MINERAL METABOLISM: Edited by Aline Martin and Rosa M. A. Moyses</subject></subj-group></article-categories><title-group><article-title>Fibroblast growth factor 23 as a risk factor for incident diabetes</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>de Borst</surname><given-names initials="MH">Martin H.</given-names></name></contrib></contrib-group><aff>Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands</aff><author-notes><corresp>Correspondence to Martin H. de Borst, MD, PhD, FERA, Department of Internal Medicine, Division of Nephrology, University Medical Center Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. Tel: +31 50 361 6161; e-mail: <email>m.h.de.borst@umcg.nl</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>15</day><month>4</month><year>2025</year></pub-date><volume>34</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">490121</issue-id><fpage>284</fpage><lpage>290</lpage><pub-history><event event-type="pmc-release"><date><day>07</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>08</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-08 00:25:14.063"><day>08</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0</ext-link></license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="conhy-34-284.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="conhy-34-284.pdf"/><abstract><sec><title>Purpose of review</title><p>Diabetes is a major global health concern, affecting millions and increasing morbidity and mortality. Recent research highlights fibroblast growth factor 23 (FGF23) as a potential contributor to type 2 diabetes and its cardiovascular complications. This review explores the role of FGF23 in metabolic and cardiovascular dysfunction and discusses possible therapeutic interventions.</p></sec><sec><title>Recent findings</title><p>Deregulated FGF23 is linked to insulin resistance, pancreatic &#946;-cell dysfunction, and systemic inflammation. Studies suggest FGF23 influences glucose metabolism via insulin signaling, oxidative stress, and inflammation. Epidemiological data indicate that elevated FGF23 levels are associated with an increased risk of type 2 diabetes and posttransplant diabetes, independent of traditional risk factors. Higher FGF23 levels have also been linked with an increased cardiovascular risk in patients with diabetes, even without chronic kidney disease.</p></sec><sec sec-type="summary"><title>Summary</title><p>FGF23 is emerging as a key factor in the cardiovascular-kidney-metabolic syndrome, connecting diabetes and cardiovascular disease. While studies suggest consistent associations, causal mechanisms remain unclear. No therapies specifically target FGF23 to lower diabetes risk, but fibroblast growth factor receptor 4 (FGFR4) inhibitors show promise. Future research should examine the role of FGF23 in individuals with normal kidney function and explore whether modifying its levels could reduce diabetes and cardiovascular risk.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>cardiovascular-kidney-metabolic syndrome</kwd><kwd>diabetes</kwd><kwd>insulin resistance</kwd><kwd>mineral metabolism</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Diabetes is among the most common noncommunicable diseases, affecting one in ten individuals or 537 million adults worldwide in 2021 [<xref rid="R1" ref-type="bibr">1</xref>]. This figure is expected to rise to 643 million by 2030 and to 783 million by 2045. Diabetes can lead to microvascular (retinopathy, neuropathy, nephropathy) and macrovascular (peripheral vascular disease, stroke, and coronary artery disease) complications, driving a three-fold increased risk of developing cardiovascular disease, compared to individuals without diabetes [<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref>]. Given the major impact of diabetes and its complications on patient outcomes and healthcare resources, diabetes prevention strategies are a major focus of research.</p><p>Risk factors for the development of type 2 diabetes, the most common form of diabetes, include overweight/obesity, age over 45, a positive family history, physical inactivity and ethnicity. The presence of metabolic dysfunction-associated fatty liver disease (MAFLD) also predisposes to the development of type 2 diabetes. In patients who already have type 2 diabetes, the risk of cardiovascular events is driven by traditional risk factors such as dyslipidemia, smoking, and hypertension, as well as other factors including diabetic nephropathy. Calcification of the vascular media wall is one of the hallmarks of advanced diabetes, and the presence of extensive vascular calcifications is an independent predictor of adverse cardiovascular outcomes, both in individuals with and without diabetes [<xref rid="R4" ref-type="bibr">4</xref>]. While the pathophysiology of media calcification in diabetes has not yet been fully elucidated, several mechanisms seem to play a role. First, media calcification is considered a process of hydroxyapatite mineralization within the medial layer. The loss of endogenous mineralization inhibitors such as matrix gla protein and pyrophosphate has been associated with vascular stiffness and calcification in type 2 diabetes [<xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref>]. Vascular smooth muscle cells can undergo a phenotypic change towards osteoblast-like cells that express and release osteochondric proteins [<xref rid="R7" ref-type="bibr">7</xref>]. Lastly, elevated plasma calcium or phosphorus levels promote apatite nucleation and crystal growth, further promoting vascular calcification.</p><p>It has been known since the 1980s that patients with type 2 diabetes have a lower bone mass, compared to individuals without diabetes [<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R9" ref-type="bibr">9</xref>]. Some studies suggested that these bone abnormalities, that also contribute to an increased fracture risk in type 2 diabetes, are related to co-existing microvascular complications [<xref rid="R10" ref-type="bibr">10</xref>]. At the same time, several studies point towards discrete yet detectable changes in mineral metabolism that already start to occur in early diabetes. These changes include lower levels of parathyroid hormone and higher levels of the phosphaturic hormone fibroblast growth factor 23 (FGF23) [<xref rid="R11" ref-type="bibr">11</xref>]. Of note, more recent studies also point towards a potential role for FGF23 as a risk factor, or potentially even a contributor to, the development of diabetes. Thus, a potential dual role for FGF23 (deregulation) has been proposed in both the development of type 2 diabetes and its complications.</p><p>Therefore, the aim of this review is to provide an overview of the present literature on FGF23 as a risk factor for type 2 diabetes, as well as the implications of deregulated FGF23 for cardiovascular risk in patients with diabetes.&#160;</p><fig position="float" id="FB1" orientation="portrait"><label>Box 1</label><caption><p>no caption available</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="conhy-34-284-g001.jpg"/></fig></sec><sec><title>PHYSIOLOGY OF FIBROBLAST GROWTH FACTOR 23</title><p>Long before the discovery of the phosphaturic hormone FGF23 it was recognized that a phosphatonin must exist to regulate phosphate excretion. In the year 2000, mutations in the <italic toggle="yes">FGF23</italic> gene that render the protein resistant to proteolytic cleavage were identified as the cause of the rare disease autosomal dominant hypophosphatemic rickets (ADHR) [<xref rid="R12" ref-type="bibr">12</xref>]. FGF23 is a circulating hormone that participates in the regulation of phosphate by decreasing phosphate reabsorption in the proximal tubuli of the kidney, and in the regulation of vitamin D metabolism by suppressing expression of the enzyme 1-alpha hydroxylase [<xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref>]. Subsequently, excessive FGF23 levels were also discovered to be a causative factor in X-linked hypophosphatemic rickets and tumor-induced osteomalacia [<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref>].</p><p>FGF23 is predominantly expressed and secreted by osteocytes in bone. FGF23 signaling can take place through several routes: a canonical route where FGF23 binds to the FGF receptor 1c (FGFR1c) at the proximal tubule in the presence of the co-factor Klotho, inducing phosphaturia and suppressing vitamin D activation; a klotho-independent route through another FGF receptor (FGFR4), activating distinct intracellular pathways (calcineurin/NFAT), promoting left ventricular hypertrophy in the heart, and through a noncanonical route involving a circulating, soluble form of Klotho that can also bind to FGF23 receptors [<xref rid="R17" ref-type="bibr">17<sup>&#9642;</sup></xref>]. Finally, Klotho can convert the FGFR1(IIIc) receptor into a specific FGF23 receptor [<xref rid="R18" ref-type="bibr">18</xref>]. FGF23 can be cleaved into C-terminal fragments that may serve specific roles, such as increasing the bioavailability of iron during inflammation [<xref rid="R19" ref-type="bibr">19</xref><sup>&#9642;&#9642;</sup>].</p><p>Patients with impaired kidney function have higher circulating FGF23 levels, compared to those with normal kidney function [<xref rid="R20" ref-type="bibr">20</xref>]. Moreover, higher levels of FGF23 have been strongly linked with an increased mortality risk in hemodialysis patients [<xref rid="R21" ref-type="bibr">21</xref>]; a finding that was later replicated in various chronic kidney disease (CKD) and non-CKD populations. FGF23 levels increase relatively early during CKD, before other components of mineral metabolism such as PTH, phosphate start to rise.</p><p>In addition to the effects of FGF23 on phosphate and vitamin D metabolism, additional effects (so-called &#8220;off-target effects&#8221;) have been described. Animal studies have shown that FGF23 can induce left ventricular hypertrophy (LVH) through FGFR4 [<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref>], and in patients higher FGF23 levels predispose to development of LVH [<xref rid="R24" ref-type="bibr">24</xref>&#8211;<xref rid="R26" ref-type="bibr">26</xref>]. Further, FGF23 has been linked with impaired glucose metabolism. This link has been established by the observation that Fgf23-knockout mice are hypoglycemic and have profoundly increased peripheral insulin sensitivity and improved subcutaneous glucose tolerance [<xref rid="R27" ref-type="bibr">27</xref>]. These abnormalities were absent in Fgf23/vitamin D receptor double-knockout mice, indicating that vitamin D mediates the relationship between FGF23 and glucose metabolism [<xref rid="R27" ref-type="bibr">27</xref>]. Moreover, HYP-mice with a PHEX (phosphate regulating gene with homologies to endopeptidases located on the X chromosome) mutation that leads to FGF23 overexpression also display hyperglycemia and hypoinsulinemia [<xref rid="R28" ref-type="bibr">28</xref>]. Klotho mutant (kl/kl) mice display decreased pancreatic insulin content and increased insulin sensitivity, compared to heterozygous and wild-type mice [<xref rid="R29" ref-type="bibr">29</xref>]. In contrast, mice with Klotho overexpression have higher blood insulin levels, require less glucose infusion to maintain blood glucose levels, and show significantly less pronounced hypoglycemic responses to insulin and insulin-like growth factor-1, compared to wild-type mice [<xref rid="R30" ref-type="bibr">30</xref>].</p></sec><sec><title>FIBROBLAST GROWTH FACTOR 23 AND (DEREGULATED) GLUCOSE HOMEOSTASIS IN HUMANS</title><p>Deregulated FGF23 and klotho are involved in impaired insulin signaling and insulin resistance through various potential mechanisms (Fig. <xref rid="F1" ref-type="fig">1</xref>). In the setting of insulin resistance, insulin signaling is impaired at the level of tyrosine phosphorylation of insulin receptor substrate (IRS)-1, which leads to downregulation of the phosphatidylinositol 3 kinase (PI3K)/AKT pathway and subsequent muscle wasting. Klotho seems to interfere with insulin receptor signaling and downstream processes, contributing to muscle wasting and insulin resistance [<xref rid="R31" ref-type="bibr">31<sup>&#9642;</sup></xref>,<xref rid="R32" ref-type="bibr">32<sup>&#9642;</sup></xref>,<xref rid="R33" ref-type="bibr">33</xref>]. Furthermore, higher plasma FGF23 levels have been linked with a higher BMI and insulin resistance in both healthy individuals and patients with diabetes (Table <xref rid="T1" ref-type="table">1</xref>).</p><fig position="float" id="F1" orientation="portrait"><label>FIGURE 1</label><caption><p>Hypothesized mechanisms of FGF23-induced incident diabetes. Overview of proposed mechanisms by which a higher plasma FGF23 level could lead to an increased risk of type 2 diabetes. Details are provided in the text. FGF23, fibroblast growth factor 23.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="conhy-34-284-g002.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>Cross-sectional studies linking FGF23 with parameters of glucose metabolism and insulin resistance</p></caption><table frame="hsides" rules="groups" border="0"><thead><tr><td align="left" rowspan="1" colspan="1">Population</td><td align="left" rowspan="1" colspan="1">Parameter(s) associated with FGF23</td><td align="center" rowspan="1" colspan="1">Reference</td></tr></thead><tbody><tr><td align="left" colspan="3" rowspan="1">Total FGF23 (C-terminal and intact FGF23)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;General population</td><td align="left" rowspan="1" colspan="1">BMI, fat mass, insulin sensitivity, HOMA-IR, postload OGTT</td><td align="center" rowspan="1" colspan="1">[<xref rid="R51" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;General population</td><td align="left" rowspan="1" colspan="1">Glucose, insulin, proinsulin</td><td align="center" rowspan="1" colspan="1">[<xref rid="R52" ref-type="bibr">52</xref><sup>&#9642;&#9642;</sup>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Stage 3&#8211;5 CKD</td><td align="left" rowspan="1" colspan="1">Insulin resistance</td><td align="center" rowspan="1" colspan="1">[<xref rid="R55" ref-type="bibr">55</xref>]</td></tr><tr><td align="left" colspan="3" rowspan="1">Intact FGF23</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;General population</td><td align="left" rowspan="1" colspan="1">BMI, insulin sensitivity</td><td align="center" rowspan="1" colspan="1">[<xref rid="R51" ref-type="bibr">51</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Obese adolescents</td><td align="left" rowspan="1" colspan="1">Insulin resistance, HOMA-IR</td><td align="center" rowspan="1" colspan="1">[<xref rid="R65" ref-type="bibr">65</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Type 2 diabetes</td><td align="left" rowspan="1" colspan="1">Serum resistin levels</td><td align="center" rowspan="1" colspan="1">[<xref rid="R66" ref-type="bibr">66</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">&#8195;Stage 3&#8211;5 CKD</td><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td align="center" rowspan="1" colspan="1">[<xref rid="R54" ref-type="bibr">54</xref>]</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>BMI, body mass index; CKD, chronic kidney disease; FGF23, fibroblast growth factor 23; HOMA-IR, homeostasis model assessment of insulin resistance; OGTT, oral glucose tolerance test.</p></fn></table-wrap-foot></table-wrap><p>Another route by which FGF23 may contribute to the risk of diabetes is via direct and indirect effects on pancreatic &#946;-cell function. One such effect is through ferroptosis, a form of nonapoptotic regulated cell death accompanied by iron-dependent lipid peroxide accumulation. Ferroptosis is involved in impaired glucose-induced insulin secretion [<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref>], and FGF C-terminal fragments promote ferroptosis [<xref rid="R19" ref-type="bibr">19</xref><sup>&#9642;&#9642;</sup>]. These results pointing towards a potentially deleterious effect of FGF23 on pancreatic &#946;-cells were recently balanced by another study suggesting that FGF23 partially protects &#946;-cells against glucolipotoxicity through interactions with the stimulus-secretion cascade [<xref rid="R36" ref-type="bibr">36</xref><sup>&#9642;&#9642;</sup>]. The same study also demonstrated that FGF23 impairs glucose-induced insulin release in murine islets [<xref rid="R36" ref-type="bibr">36</xref><sup>&#9642;&#9642;</sup>]. Thus, while these findings do not exclude the possibility that FGF23 plays a role in the development of diabetes through direct toxic effects on the pancreas, the other side of the coin could be that FGF23 provides &#946;-cell protection in established diabetes, during high-glucose and high-lipid conditions.</p><p>In addition, inflammation is an important trigger of both FGF23 production and new-onset diabetes, and as such a pro-inflammatory environment could (partly) explain higher FGF23 levels in individuals prone to develop diabetes [<xref rid="R37" ref-type="bibr">37</xref>]. Several studies have shown associations between FGF23 and markers of inflammation [<xref rid="R38" ref-type="bibr">38</xref>&#8211;<xref rid="R41" ref-type="bibr">41</xref>]. In CKD, FGF23 can directly stimulate hepatic secretion of inflammatory cytokines, potentially contributing to the pro-inflammatory milieu [<xref rid="R42" ref-type="bibr">42<sup>&#9642;</sup></xref>]. FGF23 has also been shown to contribute to inflammation in other organ systems and diseases, including pulmonary diseases such as cystic fibrosis [<xref rid="R43" ref-type="bibr">43</xref>].</p><p>Furthermore, FGF23 induces oxidative stress and cellular senescence in human mesenchymal stem cells from skeletal muscle, a mechanism potentially contributing to insulin resistance [<xref rid="R31" ref-type="bibr">31<sup>&#9642;</sup></xref>,<xref rid="R44" ref-type="bibr">44</xref>]. The FGF23 co-receptor klotho facilitates reactive oxygen species removal and confers oxidative stress resistance, potentially contributing to the antiaging properties of klotho [<xref rid="R45" ref-type="bibr">45</xref>]. Since both chronic kidney disease and oxidative stress itself can reduce klotho [<xref rid="R46" ref-type="bibr">46</xref>], a vicious cycle characterized by low klotho and increased oxidative stress could promote the risk of diabetes. Finally, FGF23 may not be a cause of incident diabetes, but rather an expression of deregulated mineral metabolism in early diabetes.</p><p>Patients with both type 1 and type 2 diabetes are more likely to display deregulations in bone and mineral metabolism including elevated FGF23 levels [<xref rid="R47" ref-type="bibr">47</xref>&#8211;<xref rid="R49" ref-type="bibr">49</xref>], compared to individuals without diabetes [<xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R50" ref-type="bibr">50</xref>]. Several cross-sectional studies have shown that circulating FGF23 levels are associated with parameters of glucose homeostasis as well as insulin sensitivity/resistance (Table <xref rid="T1" ref-type="table">1</xref>). These associations appear to be mediated by BMI [<xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R52" ref-type="bibr">52</xref><sup>&#9642;&#9642;</sup>], and weight loss is accompanied by a decrease in intact FGF23 levels [<xref rid="R51" ref-type="bibr">51</xref>]. In one study, FGF23 was positively associated with HOMA-IR, BMI and waist circumference in individuals without CKD, but not among individuals with CKD [<xref rid="R53" ref-type="bibr">53</xref>]. This may be explained by impaired kidney function, boosting FGF23 levels to very high levels and overriding potential effects related to glucose metabolism. In contrast, other studies did report associations between plasma FGF23 and insulin resistance in CKD patients [<xref rid="R54" ref-type="bibr">54</xref>,<xref rid="R55" ref-type="bibr">55</xref>]. Serum klotho levels have also been independently associated with HOMA-IR in patients with type 2 diabetes and stage 2&#8211;3 CKD [<xref rid="R56" ref-type="bibr">56</xref>].</p><p>While cross-sectional studies reviewed above strongly suggest a relationship between FGF23 levels and (deregulated) glucose homeostasis, they do not clarify whether the development of insulin resistance or diabetes drives abnormal mineral homeostasis, the opposite, or both. It is long known that insulin promotes a shift of phosphate into the intracellular compartment [<xref rid="R57" ref-type="bibr">57</xref>]. Insulin, contrary to FGF23, directly stimulates the NaPi-II co-transporter, promoting renal phosphate reabsorption at the proximal tubuli of the kidney [<xref rid="R58" ref-type="bibr">58</xref>]. Furthermore, multiple human studies have reported changes in FGF23 and phosphate in response to glucose loading (Table <xref rid="T2" ref-type="table">2</xref>). Ursem <italic toggle="yes">et al.</italic> reported that an oral glucose load in vitamin D-deficient patients with impaired glucose metabolism led to a decrease plasma (total) FGF23, which could not be attributed to changes in insulin concentration as a euglycemic-hyperinsulinemic clamp did not affect FGF23 levels [<xref rid="R59" ref-type="bibr">59<sup>&#9642;</sup></xref>]. In line, Van der Vaart <italic toggle="yes">et al.</italic> reported that oral glucose loading in nondiabetic individuals was followed by a decrease and subsequent recovery in total FGF23 levels that preceded changes in plasma phosphate levels [<xref rid="R52" ref-type="bibr">52</xref><sup>&#9642;&#9642;</sup>]. In another study in patients with type 2 diabetes, a euglycemic-hyperinsulinemic clamp led to an increase in serum FGF23 levels [<xref rid="R60" ref-type="bibr">60</xref>]. Together, these studies suggest that insulin and glucose have opposed effects on FGF23 levels, but these effects may also be context-dependent, as insulin clamping did not lead to increased FGF23 levels in individuals without diabetes [<xref rid="R60" ref-type="bibr">60</xref>]. At the same time, epidemiological studies point towards a role for FGF23 in the development of diabetes.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Reported effects of insulin and glucose on FGF23 levels</p></caption><table frame="hsides" rules="groups" border="0"><thead><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td align="center" colspan="4" rowspan="1">Effect on</td></tr><tr><td align="left" rowspan="1" colspan="1">Intervention</td><td align="left" rowspan="1" colspan="1">Population</td><td align="left" rowspan="1" colspan="1">Glucose</td><td align="left" rowspan="1" colspan="1">Insulin</td><td align="left" rowspan="1" colspan="1">FGF23</td><td align="center" rowspan="1" colspan="1">Ref</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Oral glucose loading (75 g)</td><td align="left" rowspan="1" colspan="1">Nondiabetes</td><td align="left" rowspan="1" colspan="1">&#8593;</td><td align="left" rowspan="1" colspan="1">&#8593;</td><td align="left" rowspan="1" colspan="1">&#8595;</td><td align="center" rowspan="1" colspan="1">[<xref rid="R52" ref-type="bibr">52</xref><sup>&#9642;&#9642;</sup>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Oral glucose loading (75 g)</td><td align="left" rowspan="1" colspan="1">Prediabetes</td><td align="left" rowspan="1" colspan="1">&#8593;</td><td align="left" rowspan="1" colspan="1">&#8593;</td><td align="left" rowspan="1" colspan="1">&#8595;</td><td align="center" rowspan="1" colspan="1">[<xref rid="R59" ref-type="bibr">59<sup>&#9642;</sup></xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Euglycemic-hyperinsulinemic clamp</td><td align="left" rowspan="1" colspan="1">Nondiabetes</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">&#8593;</td><td align="left" rowspan="1" colspan="1">=</td><td align="center" rowspan="1" colspan="1">[<xref rid="R60" ref-type="bibr">60</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Euglycemic-hyperinsulinemic clamp</td><td align="left" rowspan="1" colspan="1">Prediabetes</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">&#8593;</td><td align="left" rowspan="1" colspan="1">=</td><td align="center" rowspan="1" colspan="1">[<xref rid="R59" ref-type="bibr">59<sup>&#9642;</sup></xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Euglycemic-hyperinsulinemic clamp</td><td align="left" rowspan="1" colspan="1">Type 2 diabetes</td><td align="left" rowspan="1" colspan="1">=</td><td align="left" rowspan="1" colspan="1">&#8593;</td><td align="left" rowspan="1" colspan="1">&#8593;</td><td align="center" rowspan="1" colspan="1">[<xref rid="R60" ref-type="bibr">60</xref>]</td></tr></tbody></table><table-wrap-foot><fn fn-type="other"><p>FGF23, fibroblast growth factor 23.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>EPIDEMIOLOGICAL EVIDENCE CONNECTING FIBROBLAST GROWTH FACTOR 23 WITH DIABETES RISK</title><p>In line with the preceding lines of evidence that connect higher FGF23 levels with deregulated glucose metabolism and insulin resistance, several studies have demonstrated that individuals without diabetes who have a higher FGF23 level are at increased risk of developing type 2 diabetes. In a population-based cohort of 5482 participants, we found that a higher baseline C-terminal FGF23 level was associated with the development of diabetes, independent of age, sex, plasma calcium parathyroid hormone, 25(OH) vitamin D, phosphate, proinsulin and HDL cholesterol, smoking, systolic blood pressure, alcohol use and kidney function [<xref rid="R52" ref-type="bibr">52</xref><sup>&#9642;&#9642;</sup>]. Interestingly, the association between FGF23 and incident diabetes lost significance after additional adjustment for BMI and FGF23 itself was also associated with the development of obesity. Subsequently, we also found that a higher FGF23 level was associated with a higher risk of developing posttransplant diabetes in a cohort of kidney transplant recipients [<xref rid="R61" ref-type="bibr">61<sup>&#9642;</sup></xref>]. A higher plasma FGF23 level also represents a risk factor for an increased risk of premature mortality and major adverse cardiovascular events in individuals with type 2 diabetes [<xref rid="R62" ref-type="bibr">62</xref><sup>&#9642;&#9642;</sup>]. Interestingly, this association was also present in individuals with diabetes and normal or mildly impaired kidney function (eGFR &gt; 60&#8202;ml/min/1.73&#8202;m<sup>2</sup>).</p></sec><sec sec-type="conclusion"><title>CONCLUSION</title><p>The cardiovascular-kidney-metabolic syndrome, defined as a health disorder that is attributable to connections among obesity, diabetes, CKD, and cardiovascular disease, is gaining increasing attention. This review summarized recent evidence that positions the phosphaturic hormone FGF23 as a potentially important factor in the development of diabetes as well as its cardiovascular complications. Of interest, while most studies so far focused on populations with CKD, these relationships also seem to be present in individuals with normal kidney function. These initial observations should stimulate further research addressing the relationships of deregulated FGF23 and other factors involved in mineral metabolism with the risks of developing diabetes and cardiovascular disease in populations with normal kidney function.</p><p>Another question is whether lowering of FGF23 might reduce the risk of developing diabetes. Unfortunately, no specific therapies are available to reduce plasma FGF23, block its receptors or increase levels of klotho in patients. While a high-calcium and phosphate diet-induced increase in plasma FGF23 did not influence fasting insulin and glucose concentrations [<xref rid="R59" ref-type="bibr">59<sup>&#9642;</sup></xref>], the nonspecific nature of the intervention or short follow-up (3 days) may have blunted potential effects of FGF23. Of interest, FGFR4 inhibitors are currently being developed and tested in cancer, opening potential for downstream targeting of high FGF23 levels in CKD patients to prevent the development of left ventricular hypertrophy and heart failure [<xref rid="R63" ref-type="bibr">63</xref>,<xref rid="R64" ref-type="bibr">64</xref><sup>&#9642;&#9642;</sup>].</p><p>Overall, FGF23 has a well documented role as a regulator of mineral metabolism as well as a cardiovascular risk factor in CKD. Beyond that, emerging data suggest that deregulated FGF23 contributes to the cardiovascular-kidney-metabolic syndrome through various mechanisms, including the risk of developing diabetes. The exact role of FGF23 in individuals with normal kidney function remains to be addressed in future studies, paving the way for intervention studies as more specific therapies become available.</p></sec><sec><title>Acknowledgements</title><p>
<italic toggle="yes">None.</italic>
</p><sec><title>Financial support and sponsorship</title><p>
<italic toggle="yes">None.</italic>
</p></sec><sec sec-type="COI-statement"><title>Conflicts of interest</title><p>
<italic toggle="yes">There are no conflicts of interest.</italic>
</p></sec></sec></body><back><sec><title>REFERENCES AND RECOMMENDED READING</title><p>Papers of particular interest, published within the annual period of review, have been highlighted as:</p><list list-type="simple"><list-item><p>&#9642; of special interest</p></list-item><list-item><p>&#9642;&#9642; of outstanding interest</p></list-item></list></sec><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><mixed-citation publication-type="book"><comment>International Diabetes Federation. IDF diabetes atlas. 10th ed. Brussels, Belgium; 2021. Available at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.diabetesatlas.org/" ext-link-type="uri">https://www.diabetesatlas.org/</ext-link></comment>.</mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kannel</surname><given-names>WB</given-names></name><name name-style="western"><surname>McGee</surname><given-names>DL</given-names></name></person-group>. <article-title>Diabetes and cardiovascular disease: the Framingham study</article-title>. <source>JAMA</source><year>1979</year>; <volume>241</volume>:<fpage>2035</fpage>&#8211;<lpage>2038</lpage>.<pub-id pub-id-type="pmid">430798</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.241.19.2035</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tancredi</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosengren</surname><given-names>A</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Excess mortality among persons with type 2 diabetes</article-title>. <source>N Engl J Med</source><year>2015</year>; <volume>373</volume>:<fpage>1720</fpage>&#8211;<lpage>1732</lpage>.<pub-id pub-id-type="pmid">26510021</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1504347</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raggi</surname><given-names>P</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Berman</surname><given-names>DS</given-names></name><name name-style="western"><surname>Callister</surname><given-names>TQ</given-names></name></person-group>. <article-title>Prognostic value of coronary artery calcium screening in subjects with and without diabetes</article-title>. <source>J Am Coll Cardiol</source><year>2004</year>; <volume>43</volume>:<fpage>1663</fpage>&#8211;<lpage>1669</lpage>.<pub-id pub-id-type="pmid">15120828</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2003.09.068</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sardana</surname><given-names>M</given-names></name><name name-style="western"><surname>Vasim</surname><given-names>I</given-names></name><name name-style="western"><surname>Varakantam</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Inactive matrix Gla-protein and arterial stiffness in type 2 diabetes mellitus</article-title>. <source>Am J Hypertens</source><year>2017</year>; <volume>30</volume>:<fpage>196</fpage>&#8211;<lpage>201</lpage>.<pub-id pub-id-type="pmid">27927630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ajh/hpw146</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liabeuf</surname><given-names>S</given-names></name><name name-style="western"><surname>Olivier</surname><given-names>B</given-names></name><name name-style="western"><surname>Vemeer</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Vascular calcification in patients with type 2 diabetes: the involvement of matrix Gla protein</article-title>. <source>Cardiovasc Diabetol</source><year>2014</year>; <volume>13</volume>:<fpage>9</fpage>.<pub-id pub-id-type="pmid">24762216</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2840-13-85</pub-id><pub-id pub-id-type="pmcid">PMC4017083</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tyson</surname><given-names>KL</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>JL</given-names></name><name name-style="western"><surname>McNair</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Osteo/chondrocytic transcription factors and their target genes exhibit distinct patterns of expression in human arterial calcification</article-title>. <source>Arterioscler Thromb Vasc Biol</source><year>2003</year>; <volume>23</volume>:<fpage>489</fpage>&#8211;<lpage>494</lpage>.<pub-id pub-id-type="pmid">12615658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.ATV.0000059406.92165.31</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vincenti</surname><given-names>F</given-names></name><name name-style="western"><surname>Arnaud</surname><given-names>SB</given-names></name><name name-style="western"><surname>Recker</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Parathyroid and bone response of the diabetic patient to uremia</article-title>. <source>Kidney Int</source><year>1984</year>; <volume>25</volume>:<fpage>677</fpage>&#8211;<lpage>682</lpage>.<pub-id pub-id-type="pmid">6482171</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.1984.73</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andress</surname><given-names>DL</given-names></name><name name-style="western"><surname>Hercz</surname><given-names>G</given-names></name><name name-style="western"><surname>Kopp</surname><given-names>JB</given-names></name><etal/></person-group>. <article-title>Bone histomorphometry of renal osteodystrophy in diabetic patients</article-title>. <source>J Bone Mineral Res</source><year>1987</year>; <volume>2</volume>:<fpage>525</fpage>&#8211;<lpage>531</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jbmr.5650020609</pub-id><pub-id pub-id-type="pmid">3455634</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shanbhogue</surname><given-names>VV</given-names></name><name name-style="western"><surname>Hansen</surname><given-names>S</given-names></name><name name-style="western"><surname>Frost</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Bone disease in diabetes: another manifestation of microvascular disease?</article-title><source>Lancet Diabetes Endocrinol</source><year>2017</year>; <volume>5</volume>:<fpage>827</fpage>&#8211;<lpage>838</lpage>.<pub-id pub-id-type="pmid">28546096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-8587(17)30134-1</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeung</surname><given-names>SMH</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>SJL</given-names></name><name name-style="western"><surname>Laverman</surname><given-names>GD</given-names></name><name name-style="western"><surname>De Borst</surname><given-names>MH</given-names></name></person-group>. <article-title>Fibroblast growth factor 23 and adverse clinical outcomes in type 2 diabetes: a bitter-sweet symphony</article-title>. <source>Curr Diab Rep</source><year>2020</year>; <volume>20</volume>:<fpage>50</fpage>.<pub-id pub-id-type="pmid">32857288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11892-020-01335-7</pub-id><pub-id pub-id-type="pmcid">PMC7455586</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><collab>ADHR Consortium</collab>. <article-title>Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23</article-title>. <source>Nat Genet</source><year>2000</year>; <volume>26</volume>:<fpage>345</fpage>&#8211;<lpage>348</lpage>.<pub-id pub-id-type="pmid">11062477</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/81664</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saito</surname><given-names>H</given-names></name><name name-style="western"><surname>Kusano</surname><given-names>K</given-names></name><name name-style="western"><surname>Kinosaki</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production</article-title>. <source>J Biol Chem</source><year>2003</year>; <volume>278</volume>:<fpage>2206</fpage>&#8211;<lpage>2211</lpage>.<pub-id pub-id-type="pmid">12419819</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M207872200</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimada</surname><given-names>T</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis</article-title>. <source>J Bone Miner Res</source><year>2004</year>; <volume>19</volume>:<fpage>429</fpage>&#8211;<lpage>435</lpage>.<pub-id pub-id-type="pmid">15040831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1359/JBMR.0301264</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shimada</surname><given-names>T</given-names></name><name name-style="western"><surname>Mizutani</surname><given-names>S</given-names></name><name name-style="western"><surname>Muto</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia</article-title>. <source>Proc Natl Acad Sci USA</source><year>2001</year>; <volume>98</volume>:<fpage>6500</fpage>&#8211;<lpage>6505</lpage>.<pub-id pub-id-type="pmid">11344269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.101545198</pub-id><pub-id pub-id-type="pmcid">PMC33497</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jonsson</surname><given-names>KB</given-names></name><name name-style="western"><surname>Zahradnik</surname><given-names>R</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia</article-title>. <source>N Engl J Med</source><year>2003</year>; <volume>348</volume>:<fpage>1656</fpage>&#8211;<lpage>1663</lpage>.<pub-id pub-id-type="pmid">12711740</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa020881</pub-id></mixed-citation></ref><ref id="R17"><label>17&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edmonston</surname><given-names>D</given-names></name><name name-style="western"><surname>Grabner</surname><given-names>A</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>M</given-names></name></person-group>. <collab>Excellent review summarizing the literature on FGF23 and klotho in cardiovascular disease</collab>. <article-title>FGF23 and klotho at the intersection of kidney and cardiovascular disease</article-title>. <source>Nat Rev Cardiol</source><year>2024</year>; <volume>21</volume>:<fpage>11</fpage>&#8211;<lpage>24</lpage>.<pub-id pub-id-type="pmid">37443358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41569-023-00903-0</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urakawa</surname><given-names>I</given-names></name><name name-style="western"><surname>Yamazaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Klotho converts canonical FGF receptor into a specific receptor for FGF23</article-title>. <source>Nature</source><year>2006</year>; <volume>444</volume>:<fpage>770</fpage>&#8211;<lpage>774</lpage>.<pub-id pub-id-type="pmid">17086194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature05315</pub-id></mixed-citation></ref><ref id="R19"><label>19&#9642;&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Courbon</surname><given-names>G</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Martinez-Calle</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Bone-derived C-terminal FGF23 cleaved peptides increase iron availability in acute inflammation</article-title>. <source>Blood</source><year>2023</year>; <volume>142</volume>:<fpage>106</fpage>&#8211;<lpage>118</lpage>.<pub-id pub-id-type="pmid">37053547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2022018475</pub-id><pub-id pub-id-type="pmcid">PMC10356820</pub-id></mixed-citation><note><p>This paper demonstrates the role of C-terminal FGF23 fragments that enhance iron availability during acute inflammation.</p></note></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsson</surname><given-names>T</given-names></name><name name-style="western"><surname>Nisbeth</surname><given-names>U</given-names></name><name name-style="western"><surname>Ljunggren</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers</article-title>. <source>Kidney Int</source><year>2003</year>; <volume>64</volume>:<fpage>2272</fpage>&#8211;<lpage>2279</lpage>.<pub-id pub-id-type="pmid">14633152</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1523-1755.2003.00328.x</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guti&#233;rrez</surname><given-names>OM</given-names></name><name name-style="western"><surname>Mannstadt</surname><given-names>M</given-names></name><name name-style="western"><surname>Isakova</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis</article-title>. <source>N Engl J Med</source><year>2008</year>; <volume>359</volume>:<fpage>584</fpage>&#8211;<lpage>592</lpage>.<pub-id pub-id-type="pmid">18687639</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa0706130</pub-id><pub-id pub-id-type="pmcid">PMC2890264</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faul</surname><given-names>C</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>AP</given-names></name><name name-style="western"><surname>Oskouei</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>FGF23 induces left ventricular hypertrophy</article-title>. <source>J Clin Invest</source><year>2011</year>; <volume>121</volume>:<fpage>4393</fpage>&#8211;<lpage>4408</lpage>.<pub-id pub-id-type="pmid">21985788</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI46122</pub-id><pub-id pub-id-type="pmcid">PMC3204831</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grabner</surname><given-names>A</given-names></name><name name-style="western"><surname>Amaral</surname><given-names>AP</given-names></name><name name-style="western"><surname>Schramm</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy</article-title>. <source>Cell Metab</source><year>2015</year>; <volume>22</volume>:<fpage>1020</fpage>&#8211;<lpage>1032</lpage>.<pub-id pub-id-type="pmid">26437603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2015.09.002</pub-id><pub-id pub-id-type="pmcid">PMC4670583</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jovanovich</surname><given-names>A</given-names></name><name name-style="western"><surname>Ix</surname><given-names>JH</given-names></name><name name-style="western"><surname>Gottdiener</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults</article-title>. <source>Atherosclerosis</source><year>2013</year>; <volume>231</volume>:<fpage>114</fpage>&#8211;<lpage>119</lpage>.<pub-id pub-id-type="pmid">24125420</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2013.09.002</pub-id><pub-id pub-id-type="pmcid">PMC3840534</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirza</surname><given-names>MAI</given-names></name><name name-style="western"><surname>Larsson</surname><given-names>A</given-names></name><name name-style="western"><surname>Melhus</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population</article-title>. <source>Atherosclerosis</source><year>2009</year>; <volume>207</volume>:<fpage>546</fpage>&#8211;<lpage>551</lpage>.<pub-id pub-id-type="pmid">19524924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2009.05.013</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>K</given-names></name><name name-style="western"><surname>Defilippi</surname><given-names>C</given-names></name><name name-style="western"><surname>Isakova</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23, high-sensitivity cardiac troponin, and left ventricular hypertrophy in CKD</article-title>. <source>Am J Kidney Dis</source><year>2013</year>; <volume>61</volume>:<fpage>67</fpage>&#8211;<lpage>73</lpage>.<pub-id pub-id-type="pmid">22883134</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.ajkd.2012.06.022</pub-id><pub-id pub-id-type="pmcid">PMC3525738</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hesse</surname><given-names>M</given-names></name><name name-style="western"><surname>Fr&#246;hlich</surname><given-names>LF</given-names></name><name name-style="western"><surname>Zeitz</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Ablation of vitamin D signaling rescues bone, mineral, and glucose homeostasis in Fgf-23 deficient mice</article-title>. <source>Matrix Biol</source><year>2007</year>; <volume>26</volume>:<fpage>75</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">17123805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.matbio.2006.10.003</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zelenchuk</surname><given-names>LV</given-names></name><name name-style="western"><surname>Hedge</surname><given-names>AM</given-names></name><name name-style="western"><surname>Rowe</surname><given-names>PSN</given-names></name></person-group>. <article-title>PHEX mimetic (SPR4-peptide) corrects and improves HYP and wild type mice energy-metabolism</article-title>. <source>PLoS One</source><year>2014</year>; <volume>9</volume>:<fpage>e97326</fpage>.<pub-id pub-id-type="pmid">24839967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0097326</pub-id><pub-id pub-id-type="pmcid">PMC4026222</pub-id></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Utsugi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ohno</surname><given-names>T</given-names></name><name name-style="western"><surname>Ohyama</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Decreased insulin production and increased insulin sensitivity in the klotho mutant mouse, a novel animal model for human aging</article-title>. <source>Metabolism</source><year>2000</year>; <volume>49</volume>:<fpage>1118</fpage>&#8211;<lpage>1123</lpage>.<pub-id pub-id-type="pmid">11016890</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/meta.2000.8606</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurosu</surname><given-names>H</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Clark</surname><given-names>JD</given-names></name><etal/></person-group>. <article-title>Physiology: suppression of aging in mice by the hormone Klotho</article-title>. <source>Science</source><year>2005</year>; <volume>309</volume>:<fpage>1829</fpage>&#8211;<lpage>1833</lpage>.<pub-id pub-id-type="pmid">16123266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1112766</pub-id><pub-id pub-id-type="pmcid">PMC2536606</pub-id></mixed-citation></ref><ref id="R31"><label>31&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsurer Afsar</surname><given-names>R</given-names></name><name name-style="western"><surname>Afsar</surname><given-names>B</given-names></name><name name-style="western"><surname>Ikizler</surname><given-names>TA</given-names></name></person-group>. <article-title>Fibroblast growth factor 23 and muscle wasting: a metabolic point of view</article-title>. <source>Kidney Int Rep</source><year>2023</year>; <volume>8</volume>:<fpage>1301</fpage>&#8211;<lpage>1314</lpage>.<pub-id pub-id-type="pmid">37441473</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ekir.2023.04.027</pub-id><pub-id pub-id-type="pmcid">PMC10334408</pub-id></mixed-citation><note><p>Review on the role of FGF23 in muscle waisting and metabolism.</p></note></ref><ref id="R32"><label>32&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Unger</surname><given-names>RH</given-names></name></person-group>. <article-title>Klotho-induced insulin resistance: a blessing in disguise?</article-title><source>Nat Med</source><year>2006</year>; <volume>12</volume>:<fpage>56</fpage>&#8211;<lpage>57</lpage>.<pub-id pub-id-type="pmid">16397569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm0106-56</pub-id></mixed-citation><note><p>Viewpoint addressing the relationship between klotho and insulin resistance.</p></note></ref><ref id="R33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>You</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Soluble Klotho improves hepatic glucose and lipid homeostasis in type 2 diabetes</article-title>. <source>Mol Ther Methods Clin Dev</source><year>2020</year>; <volume>18</volume>:<fpage>811</fpage>&#8211;<lpage>823</lpage>.<pub-id pub-id-type="pmid">32953932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtm.2020.08.002</pub-id><pub-id pub-id-type="pmcid">PMC7479259</pub-id></mixed-citation></ref><ref id="R34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sha</surname><given-names>W</given-names></name><name name-style="western"><surname>Hu</surname><given-names>F</given-names></name><name name-style="western"><surname>Xi</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Mechanism of ferroptosis and its role in type 2 diabetes mellitus</article-title>. <source>J Diabetes Res</source><year>2021</year>; <volume>2021</volume>:<fpage>9999612</fpage>.<pub-id pub-id-type="pmid">34258295</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2021/9999612</pub-id><pub-id pub-id-type="pmcid">PMC8257355</pub-id></mixed-citation></ref><ref id="R35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bruni</surname><given-names>A</given-names></name><name name-style="western"><surname>Pepper</surname><given-names>AR</given-names></name><name name-style="western"><surname>Pawlick</surname><given-names>RL</given-names></name><etal/></person-group>. <article-title>Ferroptosis-inducing agents compromise in vitro human islet viability and function</article-title>. <source>Cell Death Dis</source><year>2018</year>; <volume>9</volume>:<fpage>595</fpage>.<pub-id pub-id-type="pmid">29789532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-018-0506-0</pub-id><pub-id pub-id-type="pmcid">PMC5964226</pub-id></mixed-citation></ref><ref id="R36"><label>36&#9642;&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pajaziti</surname><given-names>B</given-names></name><name name-style="western"><surname>Yosy</surname><given-names>K</given-names></name><name name-style="western"><surname>Steinberg</surname><given-names>OV</given-names></name><name name-style="western"><surname>D&#252;fer</surname><given-names>M</given-names></name></person-group>. <article-title>FGF-23 protects cell function and viability in murine pancreatic islets challenged by glucolipotoxicity</article-title>. <source>Pflugers Arch</source><year>2023</year>; <volume>475</volume>:<fpage>309</fpage>&#8211;<lpage>322</lpage>.<pub-id pub-id-type="pmid">36437429</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00424-022-02772-x</pub-id><pub-id pub-id-type="pmcid">PMC9908675</pub-id></mixed-citation><note><p>Highly relevant study addressing the effects of FGF23 on function and viability in pancreatic islets. It showed that FGF23 reduces insulin release in response to glucose, and also that FGF23 can activate compensatory mechanisms to maintain beta-cell function and islet integrity.</p></note></ref><ref id="R37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>V</given-names></name><name name-style="western"><surname>Martin</surname><given-names>A</given-names></name><name name-style="western"><surname>Isakova</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production</article-title>. <source>Kidney Int</source><year>2016</year>; <volume>89</volume>:<fpage>135</fpage>&#8211;<lpage>146</lpage>.<pub-id pub-id-type="pmid">26535997</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ki.2015.290</pub-id><pub-id pub-id-type="pmcid">PMC4854810</pub-id></mixed-citation></ref><ref id="R38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendoza</surname><given-names>JM</given-names></name><name name-style="western"><surname>Isakova</surname><given-names>T</given-names></name><name name-style="western"><surname>Ricardo</surname><given-names>AC</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23 and inflammation in CKD</article-title>. <source>Clin J Am Soc Nephrol</source><year>2012</year>; <volume>7</volume>:<fpage>1155</fpage>&#8211;<lpage>1162</lpage>.<pub-id pub-id-type="pmid">22554719</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2215/CJN.13281211</pub-id><pub-id pub-id-type="pmcid">PMC3386678</pub-id></mixed-citation></ref><ref id="R39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munoz Mendoza</surname><given-names>J</given-names></name><name name-style="western"><surname>Isakova</surname><given-names>T</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease</article-title>. <source>Kidney Int</source><year>2017</year>; <volume>91</volume>:<fpage>711</fpage>&#8211;<lpage>719</lpage>.<pub-id pub-id-type="pmid">28017325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2016.10.021</pub-id><pub-id pub-id-type="pmcid">PMC5313324</pub-id></mixed-citation></ref><ref id="R40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanks</surname><given-names>L</given-names></name><name name-style="western"><surname>Casazza</surname><given-names>K</given-names></name></person-group>. <article-title>Judd S, one NJP, 2015 undefined. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults</article-title>. <source>PLoS One</source><year>2015</year>; <volume>10</volume>:<fpage>e0122885</fpage>.<pub-id pub-id-type="pmid">25811862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0122885</pub-id><pub-id pub-id-type="pmcid">PMC4374938</pub-id></mixed-citation></ref><ref id="R41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallquist</surname><given-names>C</given-names></name><name name-style="western"><surname>Mansouri</surname><given-names>L</given-names></name><name name-style="western"><surname>Norrb&#228;ck</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Associations of fibroblast growth factor 23 with markers of inflammation and leukocyte transmigration in chronic kidney disease</article-title>. <source>Nephron</source><year>2018</year>; <volume>138</volume>:<fpage>287</fpage>&#8211;<lpage>295</lpage>.<pub-id pub-id-type="pmid">29301137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000485472</pub-id></mixed-citation></ref><ref id="R42"><label>42&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Grabner</surname><given-names>A</given-names></name><name name-style="western"><surname>Yanucil</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease</article-title>. <source>Kidney Int</source><year>2016</year>; <volume>90</volume>:<fpage>985</fpage>&#8211;<lpage>996</lpage>.<pub-id pub-id-type="pmid">27457912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2016.05.019</pub-id><pub-id pub-id-type="pmcid">PMC5065745</pub-id></mixed-citation><note><p>Experimental study demonstrating pro-inflammatory effects of FGF23.</p></note></ref><ref id="R43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krick</surname><given-names>S</given-names></name><name name-style="western"><surname>Grabner</surname><given-names>A</given-names></name><name name-style="western"><surname>Baumlin</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23 and Klotho contribute to airway inflammation</article-title>. <source>Eur Resp J</source><year>2018</year>; <volume>52</volume>:<fpage>1800236</fpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1183/13993003.00236-2018</pub-id><pub-id pub-id-type="pmcid">PMC6044452</pub-id><pub-id pub-id-type="pmid">29748308</pub-id></mixed-citation></ref><ref id="R44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sato</surname><given-names>C</given-names></name><name name-style="western"><surname>Iso</surname><given-names>Y</given-names></name><name name-style="western"><surname>Mizukami</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor-23 induces cellular senescence in human mesenchymal stem cells from skeletal muscle</article-title>. <source>Biochem Biophys Res Commun</source><year>2016</year>; <volume>470</volume>:<fpage>657</fpage>&#8211;<lpage>662</lpage>.<pub-id pub-id-type="pmid">26797283</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2016.01.086</pub-id></mixed-citation></ref><ref id="R45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Clark</surname><given-names>JD</given-names></name><name name-style="western"><surname>Pastor</surname><given-names>JV</given-names></name><etal/></person-group>. <article-title>Regulation of oxidative stress by the antiaging hormone klotho</article-title>. <source>J Biol Chem</source><year>2005</year>; <volume>280</volume>:<fpage>38029</fpage>&#8211;<lpage>38034</lpage>.<pub-id pub-id-type="pmid">16186101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M509039200</pub-id><pub-id pub-id-type="pmcid">PMC2515369</pub-id></mixed-citation></ref><ref id="R46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christov</surname><given-names>M</given-names></name><name name-style="western"><surname>Neyra</surname><given-names>JA</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Leaf</surname><given-names>DE</given-names></name></person-group>. <article-title>Fibroblast growth factor 23 and Klotho in AKI</article-title>. <source>Semin Nephrol</source><year>2019</year>; <volume>39</volume>:<fpage>57</fpage>&#8211;<lpage>75</lpage>.<pub-id pub-id-type="pmid">30606408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.semnephrol.2018.10.005</pub-id></mixed-citation></ref><ref id="R47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>JS</given-names></name><name name-style="western"><surname>Vilaca</surname><given-names>T</given-names></name></person-group>. <article-title>Obesity type 2 diabetes and bone in adults</article-title>. <source>Calcif Tissue Int</source><year>2017</year>; <volume>100</volume>:<fpage>528</fpage>&#8211;<lpage>535</lpage>.<pub-id pub-id-type="pmid">28280846</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00223-016-0229-0</pub-id><pub-id pub-id-type="pmcid">PMC5394147</pub-id></mixed-citation></ref><ref id="R48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kasperk</surname><given-names>C</given-names></name><name name-style="western"><surname>Georgescu</surname><given-names>C</given-names></name><name name-style="western"><surname>Nawroth</surname><given-names>P</given-names></name></person-group>. <article-title>Diabetes mellitus and bone metabolism</article-title>. <source>Exp Clin Endocrinol Diab</source><year>2017</year>; <volume>125</volume>:<fpage>213</fpage>&#8211;<lpage>217</lpage>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-0042-123036</pub-id><pub-id pub-id-type="pmid">28073133</pub-id></mixed-citation></ref><ref id="R49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vermeulen</surname><given-names>S</given-names></name><name name-style="western"><surname>Scheffer-Rath</surname><given-names>MEA</given-names></name><name name-style="western"><surname>Besouw</surname><given-names>MTP</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23 and calcium-phosphate metabolism in relation to cardiovascular risk factors in patients with type 1 diabetes</article-title>. <source>J Diabetes</source><year>2024</year>; <volume>16</volume>:<fpage>e13500</fpage>.<pub-id pub-id-type="pmid">38124483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1753-0407.13500</pub-id><pub-id pub-id-type="pmcid">PMC11128753</pub-id></mixed-citation></ref><ref id="R50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahl</surname><given-names>P</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H</given-names></name><name name-style="western"><surname>Scialla</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Earlier onset and greater severity of disordered mineral metabolism in diabetic patients with chronic kidney disease</article-title>. <source>Diabetes Care</source><year>2012</year>; <volume>35</volume>:<fpage>994</fpage>&#8211;<lpage>1001</lpage>.<pub-id pub-id-type="pmid">22446176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc11-2235</pub-id><pub-id pub-id-type="pmcid">PMC3329844</pub-id></mixed-citation></ref><ref id="R51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fern&#225;ndez-Real</surname><given-names>JM</given-names></name><name name-style="western"><surname>Puig</surname><given-names>J</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Iron and obesity status-associated insulin resistance influence circulating fibroblast-growth factor-23 concentrations</article-title>. <source>PLoS One</source><year>2013</year>; <volume>8</volume>:<fpage>e58961</fpage>.<pub-id pub-id-type="pmid">23555610</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0058961</pub-id><pub-id pub-id-type="pmcid">PMC3605441</pub-id></mixed-citation></ref><ref id="R52"><label>52&#9642;&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Der Vaart</surname><given-names>A</given-names></name><name name-style="western"><surname>Eelderink</surname><given-names>C</given-names></name><name name-style="western"><surname>Van Beek</surname><given-names>AP</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23, glucose homeostasis, and incident diabetes: findings of 2 cohort studies</article-title>. <source>J Clin Endocrinol Metab</source><year>2023</year>; <volume>108</volume>:<fpage>971</fpage>&#8211;<lpage>978</lpage>.<pub-id pub-id-type="pmid">37139691</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/clinem/dgad246</pub-id><pub-id pub-id-type="pmcid">PMC10505526</pub-id></mixed-citation><note><p>This study demonstrates that in healthy individuals, higher plasma FGF23 is associated with a higher risk of diabetes. FGF23 was also associated with a higher risk of obesity.</p></note></ref><ref id="R53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanks</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Casazza</surname><given-names>K</given-names></name><name name-style="western"><surname>Judd</surname><given-names>SE</given-names></name><etal/></person-group>. <article-title>Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults</article-title>. <source>PLoS One</source><year>2015</year>; <volume>10</volume>:<fpage>e0122885</fpage>.<pub-id pub-id-type="pmid">25811862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0122885</pub-id><pub-id pub-id-type="pmcid">PMC4374938</pub-id></mixed-citation></ref><ref id="R54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fayed</surname><given-names>A</given-names></name><name name-style="western"><surname>El Nokeety</surname><given-names>MM</given-names></name><name name-style="western"><surname>Heikal</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients</article-title>. <source>Ren Fail</source><year>2018</year>; <volume>40</volume>:<fpage>226</fpage>&#8211;<lpage>230</lpage>.<pub-id pub-id-type="pmid">29619868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/0886022X.2018.1455594</pub-id><pub-id pub-id-type="pmcid">PMC6014287</pub-id></mixed-citation></ref><ref id="R55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garland</surname><given-names>JS</given-names></name><name name-style="western"><surname>Holden</surname><given-names>RM</given-names></name><name name-style="western"><surname>Ross</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3-5 chronic kidney disease patients</article-title>. <source>J Diabetes Complications</source><year>2014</year>; <volume>28</volume>:<fpage>61</fpage>&#8211;<lpage>65</lpage>.<pub-id pub-id-type="pmid">24125760</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdiacomp.2013.09.004</pub-id></mixed-citation></ref><ref id="R56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Silva</surname><given-names>AP</given-names></name><name name-style="western"><surname>Mendes</surname><given-names>F</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Klotho levels: association with insulin resistance and albumin-to-creatinine ratio in type 2 diabetic patients</article-title>. <source>Int Urol Nephrol</source><year>2017</year>; <volume>49</volume>:<fpage>1809</fpage>&#8211;<lpage>1814</lpage>.<pub-id pub-id-type="pmid">28677090</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11255-017-1646-3</pub-id></mixed-citation></ref><ref id="R57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanbay</surname><given-names>M</given-names></name><name name-style="western"><surname>Vervloet</surname><given-names>M</given-names></name><name name-style="western"><surname>Cozzolino</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Novel faces of fibroblast growth factor 23 (FGF23): iron deficiency, inflammation, insulin resistance, left ventricular hypertrophy, proteinuria and acute kidney injury</article-title>. <source>Calcif Tissue Int</source><year>2017</year>; <volume>100</volume>:<fpage>217</fpage>&#8211;<lpage>228</lpage>.<pub-id pub-id-type="pmid">27826644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00223-016-0206-7</pub-id></mixed-citation></ref><ref id="R58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murer</surname><given-names>H</given-names></name><name name-style="western"><surname>Hernando</surname><given-names>N</given-names></name><name name-style="western"><surname>Forster</surname><given-names>I</given-names></name><name name-style="western"><surname>Biber</surname><given-names>J</given-names></name></person-group>. <article-title>Proximal tubular phosphate reabsorption: molecular mechanisms</article-title>. <source>Physiol Rev</source><year>2000</year>; <volume>80</volume>:<fpage>1373</fpage>&#8211;<lpage>1409</lpage>.<pub-id pub-id-type="pmid">11015617</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.2000.80.4.1373</pub-id></mixed-citation></ref><ref id="R59"><label>59&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ursem</surname><given-names>SR</given-names></name><name name-style="western"><surname>Vervloet</surname><given-names>MG</given-names></name><name name-style="western"><surname>B&#252;ttler</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>The interrelation between FGF23 and glucose metabolism in humans</article-title>. <source>J Diabetes Complications</source><year>2018</year>; <volume>32</volume>:<fpage>845</fpage>&#8211;<lpage>850</lpage>.<pub-id pub-id-type="pmid">29996975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jdiacomp.2018.06.013</pub-id></mixed-citation><note><p>Intervention study in humans, showing that in vitamin D-deficient patients with impaired glucose metabolism, an oral glucose load lowered FGF23 concentrations, which could be attributed to changes in insulin concentration.</p></note></ref><ref id="R60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winther</surname><given-names>K</given-names></name><name name-style="western"><surname>Nybo</surname><given-names>M</given-names></name><name name-style="western"><surname>Vind</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Acute hyperinsulinemia is followed by increased serum concentrations of fibroblast growth factor 23 in type 2 diabetes patients</article-title>. <source>Scand J Clin Lab Invest</source><year>2012</year>; <volume>72</volume>:<fpage>108</fpage>&#8211;<lpage>113</lpage>.<pub-id pub-id-type="pmid">22133206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/00365513.2011.640407</pub-id></mixed-citation></ref><ref id="R61"><label>61&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Der Vaart</surname><given-names>A</given-names></name><name name-style="western"><surname>Kremer</surname><given-names>D</given-names></name><name name-style="western"><surname>Niekolaas</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Time-updated fibroblast growth factor 23 is predictive for posttransplant diabetes mellitus in kidney transplant recipients</article-title>. <source>J Endocr Soc</source><year>2024</year>; <volume>8</volume>:<fpage>bvae055</fpage>.<pub-id pub-id-type="pmid">38577264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/jendso/bvae055</pub-id><pub-id pub-id-type="pmcid">PMC10993900</pub-id></mixed-citation><note><p>Observational study showing that a higher plasma FGF23 level is associated with new-onset diabetes after kidney transplantation, independent of known risk factors.</p></note></ref><ref id="R62"><label>62&#9642;&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeung</surname><given-names>SMH</given-names></name><name name-style="western"><surname>Binnenmars</surname><given-names>SH</given-names></name><name name-style="western"><surname>Gant</surname><given-names>CM</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23 and mortality in patients with type 2 diabetes and normal or mildly impaired kidney function</article-title>. <source>Diabetes Care</source><year>2019</year>; <volume>42</volume>:<fpage>2151</fpage>&#8211;<lpage>2153</lpage>.<pub-id pub-id-type="pmid">31488569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc19-0528</pub-id></mixed-citation><note><p>Report demonstrating that FGF23 is associated with an increased mortality risk in individuals with type 2 diabetes and normal or mildly impaired kidney function. This shows the principle that even in the absence of (moderately to severely) impaired kidney function, FGF23 can be elevated and linked with adverse outcomes.</p></note></ref><ref id="R63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Insight into the design of FGFR4 selective inhibitors in cancer therapy: prospects and challenges</article-title>. <source>Eur J Med Chem</source><year>2024</year>; <volume>263</volume>:<fpage>115947</fpage>.<pub-id pub-id-type="pmid">37976704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejmech.2023.115947</pub-id></mixed-citation></ref><ref id="R64"><label>64&#9642;&#9642;</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fuchs</surname><given-names>MAA</given-names></name><name name-style="western"><surname>Burke</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Latic</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Fibroblast growth factor 23 and fibroblast growth factor receptor 4 promote cardiac metabolic remodeling in chronic kidney disease</article-title>. <source>Kidney Int</source><year>2025</year>; <comment>S0085-2538:00087-0</comment>.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.kint.2025.01.024</pub-id><pub-id pub-id-type="pmid">39923962</pub-id></mixed-citation><note><p>Recent study highlighting the role of FGF23 and FGFR4 in cardiac metabolic remodeling in CKD.</p></note></ref><ref id="R65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wojcik</surname><given-names>M</given-names></name><name name-style="western"><surname>Janus</surname><given-names>D</given-names></name><name name-style="western"><surname>Dolezal-Oltarzewska</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>The association of FGF23 levels in obese adolescents with insulin sensitivity</article-title>. <source>J Pediatr Endocrinol Metab</source><year>2012</year>; <volume>25</volume><issue>(7&#8211;8)</issue>:<fpage>687</fpage>&#8211;<lpage>690</lpage>.<pub-id pub-id-type="pmid">23155694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1515/jpem-2012-0064</pub-id></mixed-citation></ref><ref id="R66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakashima</surname><given-names>A</given-names></name><name name-style="western"><surname>Yokoyama</surname><given-names>K</given-names></name><name name-style="western"><surname>Kawanami</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Association between resistin and fibroblast growth factor 23 in patients with type 2 diabetes mellitus</article-title>. <source>Sci Rep</source><year>2018</year>; <volume>8</volume>:<fpage>13999</fpage>.<pub-id pub-id-type="pmid">30228288</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-018-32432-z</pub-id><pub-id pub-id-type="pmcid">PMC6143599</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>